Saturday, July 27, 2024 10:57:34 AM
Has been quoted and cited many times. From FDA guidance on external control arms:
"This guidance does not address other types of external controls, such as using summary-level estimates instead of patient-level data.
You just referring to a guideline or the FDA, just as Doclogic does, makes you an idiot. Put your money where your mouth is and start QUATION the FDA. Pock pock Pock pockPock pockPock pockPock pock chicken. from bcplatforms.com
BC Platforms’ Global Data Partner Network provides patient level, longitudinal, and geographically diverse real world data (RWD) for use as external control arms (ECAs) in randomised human clinical trials. Through the use of RWD, fewer patients are required to be directly enrolled in randomised clinical trials, enabling broader patient inclusion and shaving significant time off the clinical development process — saving cost and resource — while facilitating improved access to new drugs, in new markets, for the global patient population.
The sponsor can know results of efficacy IAs prior to datalock.
The designed in OS was between the 233 that were randomized to -L and 99 that were randomized to placebo. That failed badly.
No they didn't they improved mOS x3 vs SOC
You continue to argue it would make trials impossible to stick with this,
You twist lie cheat. It is not possible to have a normal conversation with you since you keep ignoring reliable resources and MDs, refuse to quote the FDA and twist everything that anyone says.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
